» Articles » PMID: 1415483

Morphologic Effects of HGRH Gene Expression on the Pituitary, Liver, and Pancreas of MT-hGRH Transgenic Mice. An in Situ Hybridization Analysis

Overview
Journal Am J Pathol
Publisher Elsevier
Specialty Pathology
Date 1992 Oct 1
PMID 1415483
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Morphologic changes in the pituitary, liver, and pancreas of mice with the metallothionein-human growth hormone--releasing hormone (MT-hGRH) transgene were analyzed by in situ hybridization histochemistry (ISH). There was progression from somatotroph hyperplasia to neoplasia in pituitaries of transgenic mice. Pituitary neoplasms were present between 9 to 12 months of age in some mice. Magnetic resonance imaging (MRI) readily identified enlarged pituitaries in MT-hGRH transgenic mice. Serum mouse GH and hGRH levels were marked elevated in MT-hGRH transgenic mice. In situ hybridization histochemistry showed mRNA for hGRH in liver, pituitary, pancreas, spleen, and in most other tissues examined. Combined ISH and immunohistochemistry in the pituitary gland showed that some of the GH cells also produced hGRH, and ultrastructural immunohistochemical analysis of pituitaries showed that GH and hGRH were localized in the same cell and within the same secretory granules. Liver cells of MT-hGRH transgenic mice showed evidence of hypertrophy, and the pancreatic islets were hyperplastic with significant increases in the islet cell areas. The morphologic changes in the liver were distinctive enough to separate control littermates from MT-hGRH transgenic mice in all cases. The enlarged pancreatic islets had increased numbers of insulin-producing cells. Immunoreactive hGRH and hGRH mRNA were both localized in islet cells, and an intense hybridization signal of hGRH mRNA, but only weak staining for hGRH protein, were detected in the liver of transgenic mice. These results indicate that excessive hGRH production leads to distinct morphologic changes in various organs in MT-hGRH transgenic mice and that there is temporal progression from hyperplasia to adenomatous somatotrophs in pituitaries with chronic stimulation by hGRH that involves paracrine, endocrine, and autocrine mechanisms.

Citing Articles

X-linked acrogigantism syndrome: clinical profile and therapeutic responses.

Beckers A, Lodish M, Trivellin G, Rostomyan L, Lee M, Faucz F Endocr Relat Cancer. 2015; 22(3):353-67.

PMID: 25712922 PMC: 4433400. DOI: 10.1530/ERC-15-0038.


Long- but not short-term adult-onset, isolated GH deficiency in male mice leads to deterioration of β-cell function, which cannot be accounted for by changes in β-cell mass.

Cordoba-Chacon J, Gahete M, Pokala N, Geldermann D, Alba M, Salvatori R Endocrinology. 2014; 155(3):726-35.

PMID: 24424062 PMC: 3929744. DOI: 10.1210/en.2013-1825.


Elevated GH/IGF-I, due to somatotrope-specific loss of both IGF-I and insulin receptors, alters glucose homeostasis and insulin sensitivity in a diet-dependent manner.

Gahete M, Cordoba-Chacon J, Anadumaka C, Lin Q, Bruning J, Kahn C Endocrinology. 2011; 152(12):4825-37.

PMID: 21990313 PMC: 3230054. DOI: 10.1210/en.2011-1447.


Hereditary pituitary hyperplasia with infantile gigantism.

Glasker S, Vortmeyer A, Lafferty A, Hofman P, Li J, Weil R J Clin Endocrinol Metab. 2011; 96(12):E2078-87.

PMID: 21976722 PMC: 3232621. DOI: 10.1210/jc.2011-1401.


Use of the metallothionein promoter-human growth hormone-releasing hormone (GHRH) mouse to identify regulatory pathways that suppress pituitary somatotrope hyperplasia and adenoma formation due to GHRH-receptor hyperactivation.

Luque R, Soares B, Peng X, Krishnan S, Cordoba-Chacon J, Frohman L Endocrinology. 2009; 150(7):3177-85.

PMID: 19342460 PMC: 2703537. DOI: 10.1210/en.2008-1482.


References
1.
Chirgwin J, Przybyla A, MacDonald R, Rutter W . Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 1979; 18(24):5294-9. DOI: 10.1021/bi00591a005. View

2.
Sano T, Asa S, Kovacs K . Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations. Endocr Rev. 1988; 9(3):357-73. DOI: 10.1210/edrv-9-3-357. View

3.
Asa S, Kovacs K, Stefaneanu L, Horvath E, Billestrup N, Gonzalez-Manchon C . Pituitary mammosomatotroph adenomas develop in old mice transgenic for growth hormone-releasing hormone. Proc Soc Exp Biol Med. 1990; 193(3):232-5. DOI: 10.3181/00379727-193-3-rc1. View

4.
Frohman L, Downs T, Kashio Y, Brinster R . Tissue distribution and molecular heterogeneity of human growth hormone-releasing factor in the transgenic mouse. Endocrinology. 1990; 127(5):2149-56. DOI: 10.1210/endo-127-5-2149. View

5.
Lloyd R, Cano M, Landefeld T . The effects of estrogens on tumor growth and on prolactin and growth hormone mRNA expression in rat pituitary tissues. Am J Pathol. 1988; 133(2):397-406. PMC: 1880788. View